Literature DB >> 2327658

Regulatory effect of prostaglandin E2 on fibronectin release from human alveolar macrophages.

T Ozaki1, H Moriguchi, Y Nakamura, T Kamei, S Yasuoka, T Ogura.   

Abstract

Fibronectin (Fn), which is released from several kinds of cells including alveolar macrophages (AM), is important in inflammatory reactions in the certain lung diseases such as idiopathic pulmonary fibrosis (IPF). Therefore, information on the mechanisms regulating Fn release from AM may be useful for elucidating the pathogenesis of these diseases and developing therapeutic modalities. We supposed that prostaglandin E2 (PGE2), which is known to modulate cellular functions, might be involved in regulation of Fn release, and, accordingly, we measured the release of Fn and PGE2 from AM from normal volunteers (NV), control patients (CP), and patients with IPF. AM from patients with IPF were found to release more Fn than AM from NV (IPF: 250 +/- 58.8/10(6) cells.24 h, NV: 53.0 +/- 7.3 ng/10(6) cells.24 h) and to release less PGE2 than the latter (IPF: 0.48 +/- 0.12 ng/10(6) cells.24 h, NV:1.35 +/- 0.24 ng/10(6) cells.24 h). A negative correlation was found between the contents of Fn and PGE2 in the culture media of AM from NV, CP, and patients with IPF. Lipopolysaccharide, phorbol myristate acetate, and zymosan suppressed Fn release from AM but stimulated their PGE2 release, and these effects were reversed by indomethacin. Exogenous PGE2 (greater than 1 x 10(-8) M) suppressed Fn release. The albumin-antialbumin complex stimulated Fn release but did not affect PGE2 release. These results indicate that Fn release from AM changed in response to various stimuli, and that PGE2 is important in suppressing Fn release from AM, suggesting a negative feedback mechanism of PGE2 in releasing Fn.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327658     DOI: 10.1164/ajrccm/141.4_Pt_1.965

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice.

Authors:  Kristy A Bauman; Scott H Wettlaufer; Katsuhide Okunishi; Kevin M Vannella; Joshua S Stoolman; Steven K Huang; Anthony J Courey; Eric S White; Cory M Hogaboam; Richard H Simon; Galen B Toews; Thomas H Sisson; Bethany B Moore; Marc Peters-Golden
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

Review 2.  Control of local immunity by airway epithelial cells.

Authors:  M Weitnauer; V Mijošek; A H Dalpke
Journal:  Mucosal Immunol       Date:  2015-12-02       Impact factor: 7.313

Review 3.  Myofibroblast repair mechanisms post-inflammatory response: a fibrotic perspective.

Authors:  Casimiro Gerarduzzi; John A Di Battista
Journal:  Inflamm Res       Date:  2016-12-31       Impact factor: 4.575

Review 4.  Prostaglandin E2 and the pathogenesis of pulmonary fibrosis.

Authors:  Paul D Bozyk; Bethany B Moore
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-18       Impact factor: 6.914

5.  Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis.

Authors:  M Molina-Molina; A Serrano-Mollar; O Bulbena; L Fernandez-Zabalegui; D Closa; A Marin-Arguedas; A Torrego; J Mullol; C Picado; A Xaubet
Journal:  Thorax       Date:  2006-04-06       Impact factor: 9.139

6.  Fibroblast growth factors in connective tissue disease associated interstitial lung disease.

Authors:  S C Thornton; J M Robbins; R Penny; S N Breit
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

7.  Lung fibroblast repair functions in patients with chronic obstructive pulmonary disease are altered by multiple mechanisms.

Authors:  Shinsaku Togo; Olaf Holz; Xiangde Liu; Hisatoshi Sugiura; Koichiro Kamio; Xiangqi Wang; Shin Kawasaki; Youngsoo Ahn; Karin Fredriksson; C Magnus Skold; Kai Christian Mueller; Detlef Branscheid; Lutz Welker; Henrik Watz; Helgo Magnussen; Stephen I Rennard
Journal:  Am J Respir Crit Care Med       Date:  2008-05-08       Impact factor: 21.405

8.  Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury.

Authors:  Marco Failla; Tiziana Genovese; Emanuela Mazzon; Elisa Gili; Carmelo Muià; Mariangela Sortino; Nunzio Crimi; Achille P Caputi; Salvatore Cuzzocrea; Carlo Vancheri
Journal:  Respir Res       Date:  2006-11-21

Review 9.  Lipid Mediators Regulate Pulmonary Fibrosis: Potential Mechanisms and Signaling Pathways.

Authors:  Vidyani Suryadevara; Ramaswamy Ramchandran; David W Kamp; Viswanathan Natarajan
Journal:  Int J Mol Sci       Date:  2020-06-15       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.